The Emerging Focus on Pharmacogenomics

Main Article Content

Charles Edeki


Drugs are designed to treat medical conditions for the general population. Idiosyncratic reactions to drugs are determined by the individual’s respective genetic variations that direct effectiveness and side effects. Adverse drug reactions rank within the top ten leading causes of death in the developed world. The field of pharmacogenomics has advanced in the last fifty years, picking up significant momentum with recent biotechnological developments that allow scientists to investigate the human genome and provide individualized drug therapy that will increase the efficacy of drugs and decrease the incidence of adverse drug reactions. Pharmacogenomics has reached a milestone in making personalized medicine accessible and effective. The medical community shares this responsibility for the emerging focus on pharmacogenomics with regulatory agencies and bioinformatics specialists as they struggle to streamline vast libraries of information and reconcile public and regulatory approval on this critical path to the next level of health care.

Pharmacogenomics, bioinformatics, Alleviate Adverse Drug Reactions (ADRs), biochips.

Article Details

How to Cite
Edeki, C. (2019). The Emerging Focus on Pharmacogenomics. International Journal of Biochemistry Research & Review, 27(2), 1-6.
Systematic Review Article


Ross C, Katzov H, Carleton B, Hayden M. Pharmacogenomics and its implications for autoimmune disease. Review. Journal of Autoimmunity. 2007;28(1):122-128.

Stearns V, Davidson NE, Flockhart DA. Pharmacogenetics in the treatment of breast cancer. The Pharmacogenomics Journal. 2004;4(3):143-153.

Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: Past lessons, future directions. Drug Metabolism Reviews. 2008;40(2):187-224.
DOI: 10.1080/03602530801952864

Hardiman G. Application of ultra-high throughput sequencing and microarray technologies in pharmacogenomics testing. Therapeutic Drug Monitoring (Chapter 7); 2012.

Chan A, Pirmohamed N, Comabella B. Pharmacogenomics in neurology: Current state and future steps. Annals of Neurology. 2011;70(5):684-697.
DOI: 10.1002/ana.22502

Cohen J. Overcoming regulatory and economic challenges facing pharmacogenomics. New Biotechnology. 2012;4(3):14-20.
DOI: 10.1016/j.nbt.2012.03.002

Thong BH, Teck-Choon T. Epidemiology and risk factors for drug allergy. British Journal of Clinical Pharmacology. 2011;71 (5):684-700.

Oliver C, Williams-Jones B. Pharmacogenomic technologies: A necessary “luxury” for better global public health? Globalization and Health. 2011; 7(30).
DOI: 10.1186/1744-86037-30

Hayney MS. Pharmacogenomics and infectious diseases: Impact on drug response and applications to disease management. American Journal of Health-System Pharmacy. 2002;59(17):1626-1631.

Ameen S, Qadir MI, Ahmad B. Pharmacogenomic approaches in the treatment of breast cancer by tamoxifen. Pakistan Journal of Pharmaceutical Sciences. 2012;25(2):469-476.

Kroetz D, Ahituv N, Burchard E, Guo S, Sali A, Giacomini K. The University of California Pharmacogenomics Center: At the interface of genomics, biological mechanisms and drug therapy. Pharmacogenomics. 2009;10(10):1569-1576.
DOI: 10.2217/pgs.09.119